Synergistic Therapeutic Microvesicle Systems

Publication ID: 24-11857582_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Therapeutic Microvesicle Systems,” Published Technical Disclosure No. 24-11857582_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857582_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,582.

Summary of the Inventive Concept

Integrating patented therapeutic microvesicles with AI, IoT, blockchain, and nanomaterials to create a more powerful, personalized, and efficient system for treating gastrointestinal disorders

Background and Problem Solved

The original patent disclosed therapeutic microvesicles of probiotic bacteria, but limitations in production, quality control, and patient treatment outcomes necessitate the development of more advanced systems. This inventive concept addresses these limitations by combining the patented microvesicles with cutting-edge technologies

Detailed Description of the Inventive Concept

The synergistic system comprises a therapeutic microvesicle composition, an AI-powered quality control system, a blockchain-based tracking system, a nanomaterial-based delivery system, and an IoT-enabled device for real-time monitoring. The system enables personalized treatment, enhanced microvesicle production, and secure tracking of patient outcomes. The AI-powered quality control system ensures microvesicle purity and consistency, while the blockchain-based tracking system guarantees the authenticity of the microvesicles. The nanomaterial-based delivery system targets the release of microvesicles in the gut, and the IoT-enabled device monitors treatment efficacy in real-time

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, blockchain, and nanomaterials with the patented therapeutic microvesicles, providing a non-obvious and innovative solution to the limitations of the original patent

Alternative Embodiments and Variations

Alternative embodiments may include using different AI algorithms, blockchain platforms, or nanomaterials. Variations could involve integrating the synergistic system with other healthcare technologies, such as telemedicine or electronic health records

Potential Commercial Applications and Market

The synergistic therapeutic microvesicle system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of gastrointestinal disorders. The system's ability to provide personalized, efficient, and secure treatment outcomes could revolutionize the industry and create new market opportunities

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Microbiology, probiotic biotechnology, with expertise in bacterial strain development, microvesicle production, and therapeutic applications in gastrointestinal health

Person of Ordinary Skill (PHOSITA) Profile

A researcher or biotechnologist with advanced degree in microbiology, familiar with probiotic strain manipulation, microvesicle extraction techniques, and emerging digital health technologies

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with established probiotic microvesicle systems represents a natural progression of biotechnological innovation. The combination of AI, blockchain, and nanomaterial delivery with existing bacterial strain technologies provides predictable improvements in tracking, quality control, and targeted treatment. These technological extensions represent standard engineering approaches to enhancing existing biotechnological systems.

Obvious Combinations & Variations

Source Patent Element

Isolated Bifidobacterium longum bacterial strains capable of producing therapeutic microvesicles

PTD Variation

AI-powered quality control system for monitoring microvesicle production and consistency

Obviousness Reasoning

Quality control systems are a known technique in biotechnology, and applying machine learning to biological process monitoring represents a predictable technological enhancement

Source Patent Element

Dried or lyophilized bacterial strains for microvesicle production

PTD Variation

Nanomaterial-based delivery system for targeted gut microvesicle release

Obviousness Reasoning

Targeted drug delivery using nanomaterials is a well-established approach in biotechnology, representing an obvious extension of existing microvesicle production techniques

Source Patent Element

Bacterial strains capable of inducing microvesicle production

PTD Variation

Blockchain-based tracking system for authenticating and monitoring microvesicle treatments

Obviousness Reasoning

Implementing blockchain for tracking biological products is a known technique in emerging biotechnology, providing a predictable method for ensuring product authenticity and traceability

Source Patent Element

Composition of probiotic bacterial strains

PTD Variation

IoT-enabled device for real-time monitoring of treatment efficacy

Obviousness Reasoning

Integration of monitoring technologies with biological treatments represents a standard approach in personalized medicine, offering predictable improvements in patient care

Source Patent Element

Bacterial strain cultivation techniques

PTD Variation

Machine learning algorithm for identifying optimal microvesicle compositions based on patient characteristics

Obviousness Reasoning

Personalized medicine approaches using AI for treatment optimization are well-known in biotechnology, representing an obvious technological progression

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this publication would be obvious to a Person Having Ordinary Skill In The Art based on the teachings of US Patent 11857582, as the technological extensions represent predictable combinations of known biotechnological techniques with standard digital health innovations, thereby rendering potential claims covering such integrations unpatentable as obvious variations of the prior art.

Original Patent Information

Patent Number	US 11,857,582
Title	Therapeutic microvesicles of probiotic bacteria
Assignee(s)	BioGaia AB